Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
AIM III is a prospective, randomized, double-blinded, placebo controlled trial. The study is
directly connected to IRB 08-008161 as a specific aim of the National Institute of Health
(NIH) grant. Participants may either consent to and qualify for AIM I and AIM II (IRB
08-008161) or have a cardiac catheterization with acetylcholine testing in the Cardiac
Catheterization Laboratory at Mayo Clinic in Rochester, Minnesota to be considered for this
study.
Phase:
Phase 3
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
GlaxoSmithKline National Heart, Lung, and Blood Institute (NHLBI) National Institute on Aging (NIA)